All In Biotech

Free tool

FAERS Monitor: Lotemax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 200738 or its brand name (Lotemax, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.

Reports

4,307

Serious

1,582

37% of reports

Hospitalization

543

Death reported

124

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain600
  • eye irritation483
  • off label use353
  • drug ineffective329
  • vision blurred312
  • ocular hyperaemia279
  • headache230
  • fatigue216
  • dry eye180
  • pain169
  • nausea168
  • eye swelling153
  • lacrimation increased149
  • visual impairment145
  • condition aggravated140

Reports by year received

View as table
YearReports
20048
200515
200622
200716
200833
200965
2010107
201177
2012137
201388
2014152
2015275
2016388
2017341
2018318
2019350
2020277
2021255
2022291
2023286
2024305
2025300
2026201

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,852 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal60052.548.730,007
eye irritationSignal48341.338.018,854
ocular hyperaemiaSignal27928.925.87,452
lacrimation increasedSignal14924.220.73,279
eye swellingSignal15320.217.32,761
dry eyeSignal18017.715.32,811
vision blurredSignal31211.110.02,875
visual impairmentSignal1455.74.9563
condition aggravatedSignal1402.21.997
off label use3532.01.8175
headache2301.81.682
fatigue2161.41.220
pain1691.31.215
drug ineffective3291.21.114
nausea1681.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.